Abstract -Plasmid DNA (pcDNA1::MOMP A) expressing the major outer membrane protein (MOMP) of Chlamydophila psittaci genotype A strain 89/1051 has been tested for its ability to induce protective immunity against Cp. psittaci challenge in budgerigars. Eight pairs of male and female budgerigars were housed in eight separate bird cages placed in two negative pressure isolators, four cages per group. All budgerigars were immunised twice intramuscularly with 100 lg plasmid DNA. Both groups received a primary DNA inoculation at day 0 followed by a booster inoculation 3 weeks later. Group 1 received pcDNA1::MOMP A, while group 2 received the placebo vaccine pcDNA1. Budgerigars were challenged by aerosol 2 weeks following the booster vaccination. The challenge consisted of 10 8 TCID 50 of the homologous Cp. psittaci genotype A strain. Cloacal and pharyngeal swabs of all budgerigars, taken prior to the experimental infection were negative in both PCR and culture. However, all budgerigars showed low pre-existing serum antibody titres. This indicates that animals were previously infected. Nevertheless, DNA immunisation could significantly reduce clinical signs, macroscopic lesions, pharyngeal and cloacal excretion as well as chlamydial replication, even in the presence of pre-existing serum antibodies, as compared to the placebo-vaccinated controls.
INTRODUCTION
Chlamydophila psittaci, a Gram-negative obligate intracellular pathogen, causes chlamydiosis in Psittaciformes (cockatoos, parrots, parakeets, lories) and psittacosis or parrot fever in humans. The infection is highly prevalent in Psittaciformes as studies in wild and captive Psittaciformes in North and South America, Australia, Europe and Japan have shown:
16-81% of the examined birds were positive for Cp. psittaci [2-4, 7, 10, 12, 25] . The outer membrane protein A (ompA) genotype A is found most often in these birds. The infection is also highly prevalent among captive Belgian Psittaciformes, as we recently demonstrated by examining 39 Psittaciforme breeding facilities. Fifty-nine (19.2%) of 308 Psittaciformes were positive for Cp. psittaci by nested PCR/EIA, and bacteria were isolated from 25 (42.3%) birds with PCR-positive results. Eight of 39 (20.5%) breeding facilities were positive in both nested polymerase chain reaction (PCR)/ EIA and culture, and respiratory disease was present in all these facilities [23] . Interestingly, we not only discovered ''the expected'' genotype A, but for the first time also detected genotype E/B strains in Psittaciformes [6] . Moreover, we also demonstrated the transmission of genotype E/B from African grey parrots to humans. In birds, the course of infection can be rather mild but a mortality rate of 50% or even higher is not unusual 1 .
Faecal and nasal excretions of diseased birds are the primary source of human infections [6, 13, 23] . However, apparent clinically healthy Psittaciformes also present a threat to human health, since many cockatoos, parrots, parakeets and lories never get rid of the bacterium once infected and most of them actually become Cp. psittaci carriers, shedding the bacteria again after being stressed [1, 11] . Thus, a considerable number of people are at risk of becoming infected with this bacterium such as people working in pet shops, garden centers, quarantine stations and zoos. But, also visitors of these facilities and people keeping Psittaciformes as pets can become infected. Vaccinating Psittaciformes could significantly reduce zoonotic risk. However, there is no commercial vaccine. However, DNA vaccination might be used for future vaccination of Psittaciformes, since the significance of DNA immunisation as a means of preventing severe clinical signs, lesions and bacterial excretion has already been demonstrated in a specific pathogen free turkey and chicken experimental model of Cp. psittaci infection [14, 21, 22, 24, 26] . Therefore, we evaluated the ability of plasmid DNA expressing the major outer membrane protein (MOMP) of a Cp. psittaci genotype A strain to raise protective immunity in budgerigars (Melopsittacus undulatus) experimentally infected with the homologous Cp. psittaci strain. Regarding our previous DNA vaccination results in SPF turkeys, we tried to increase the immunogenicity of the vaccine further by optimising the codon-usage.
MATERIALS AND METHODS

Cp. psittaci strain
Cp. psittaci strain 89/1051, isolated from the liver of a blue-fronted Amazon parrot (Amazona aestiva aestiva) [16] , was used. The strain was previously characterised using both serovar-specific monoclonal antibodies, ompA restriction fragment length polymorphism analysis and sequencing of the ompA gene and was classified as an avian serovar/genotype A strain [5, 16, 18] . The bacteria were grown in buffalo green monkey (BGM) cells as previously described [15] and the 50% tissue culture infective dose (TCID 50 ) was determined on BGM cells by the method of Spearman and Kaerber [8] .
DNA vaccine
Plasmid pcDNA1::MOMP A was constructed by sticky-end ligation of the ompA gene of Cp. psittaci genotype A 89/1051 into the EcoRI and BamHI site of pcDNA1 [19] . The ompA gene was obtained by PCR amplification from genomic DNA. The amplified gene, with a total length of 1 098 bp, includes the startcodon ATG and the complete last conserved region. The ompA gene was codon optimised for expression in avian cells and restriction sites were added at both ends of the ompA gene (GenScript Corporation, Piscataway, NJ, USA). The gene now has a total length of 1 110 bp.
Previously, the expression of codon-optimised ompA of Cp. psittaci strain 92/1293 was evaluated in DF-1 cells (Chicken Embryo Fibroblasts; ATC: CRL-12203) using a Polyfect Ò Transfection Kit (Qiagen, Venlo, The Netherlands). Successful codon-optimisation was shown by increased fluorescence for MOMP opt when compared to MOMP and confirmed by an increased CAI 124 from 0.698 for ompA to 0.981 for ompA opt in the chicken and from 0.606 for ompA to 0.948 for ompA opt in turkeys (unpublished results).
E. coli MC1061/P3 cells were transfected by electroporation (Gene Pulser, Bio-Rad, Nazareth, Belgium), and clones were selected on medium containing ampicillin and tetracycline and grown in microtitre plates. The presence of inserts was confirmed by EcoRI and BamHI restriction enzyme 1 Cycling conditions were as follows: denaturation for 30 s at 95°C, primer annealing for 1 min at 55°C, and primer extension for 2 min at 72°C. The sequence of the codon-optimised ompA insert was confirmed by the VIB Genetic Service Facility (University of Antwerp, Antwerp, Belgium) using vector associated T7 and SP6 priming sites.
Finally, pcDNA1 control (placebo) and pcDNA1::MOMP A were grown in MC1061/P3 and purified using the Endo Free Giga plasmid preparation method (Qiagen). DNA concentration was determined by measuring the optical density at 260 nm and was confirmed by comparing intensities of ethidium bromide-stained EcoRI/BamHI restriction endonuclease fragments with standards of known concentrations. DNA was stored at À20°C in 1 mM Tris (pH 7.8)-0.1 mM EDTA.
Expression of the ompA gene was confirmed by indirect imunofluorescence staining of DEAE dextran transfected COS-7 cells, transfected either with pcDNA1::MOMP A or pcDNA1 control plasmid, as described previously [19] . For each immunisation, 100 lg pcDNA1::MOMP A, diluted in sterile saline (0.9% NaCl) was used.
Vaccination trial
The experimental design was evaluated and approved by the Ethical Commission for Animal Experiments of Ghent University. Sixteen oneyear-old budgerigars were purchased from a private breeding facility in East-Flanders. We used conventional budgerigars, since SPF Psittaciformes are unavailable. Pharyngeal swabs of all birds of this breeding facility were negative in a Cp. psittaci species-specific nested PCR/EIA and in culture on BGM cells [23] . Eight pairs of male and female budgerigars were housed in 8 separate bird cages placed in 2 negative pressure isolators (IM 1500, Montair, Sevenum, The Netherlands), 4 cages per unit. In this way, 2 groups of 4 bird pairs each were created. Food (seed mixture for budgerigars, food sticks, sepia shells) and water were provided ad libitum.
All budgerigars were immunised intramuscularly (m. quadriceps) with 100 lg plasmid DNA in 100 lL sterile saline (0.9% NaCl). Both groups received a primary DNA inoculation at day one and one booster inoculation 3 weeks later. Group 1 received pcDNA::MOMP A, while group 2 received the placebo vaccine pcDNA1. Budgerigars were challenged by aerosol (Cirrus Nebulizer, Intersurgical, Wokingham, Berkshire, UK) 2 weeks following the booster vaccination. The challenge consisted of 10 8 TCID 50 of the Cp. psittaci genotype A strain 89/1051.
Samples
All budgerigars were observed daily for clinical signs. Pharyngeal swabs were collected at the beginning of the experiment, at day 1 and at euthanasia, 21 days post challenge infection. Faecal excretion was evaluated at the day of challenge and subsequently every day until 20 days post challenge by taking swabs from fresh faecal droppings on the cage floor. All swabs were stored at À80°C in Cp. psittaci transport medium until tested. Blood samples for the quantification of MOMP-specific serum antibody titres were collected immediately prior to each DNA inoculation, immediately prior to the experimental infection and at the day of euthanasia. Blood samples were stored overnight at room temperature, centrifuged (325 · g, 10 min, 4°C) and afterwards serum was collected and frozen at À20°C until tested. At the time of euthanasia, 21 days post challenge, proliferative responses in spleen cells were determined. All budgerigars were examined for macroscopic lesions. Macroscopic lesions were scored (Tab. I) as previously described [17] . Cryostat tissue sections of the lungs, conchae, abdominal and thoracic airsacs, pericardium, kidney, liver and gut (caecum) were examined for the presence of chlamydial antigen.
Cp. psittaci excretion
Pharyngeal and cloacal swabs were examined for the presence of viable Cp. psittaci by culture in BGM cells, as previously described [17] . The number of BGM cells with chlamydial inclusions was counted in five randomly selected microscopy fields (Radiance 2000MP, Bio-Rad; 600·). For each cage or bird pair, the excretion was scored from 0 to 5. Score 0 indicated no chlamydophilae present; score 1 was given when a mean of 1-5 elementary bodies were DNA vaccination against Cp. psittaci 
Cp. psittaci detection in the tissue organs
Cryostat tissue sections of different organs were examined by the Imagen TM direct immunofluorescence staining (Novo Nordisk Diagnostics, Cambridge, UK), as previously described [17] . The presence of Chlamydophila antigen in tissues of the placebo-vaccinated control group and the pcDNA1:: MOMP A vaccinated group was scored as mentioned above for swab cultures.
Antibody responses
Enzyme-linked immunosorbent assays (ELISA) were performed on sera being pre-treated with kaolin to remove background activity [9] . MOMP-specific antibody titres were determined using standard protocols with rMOMP as antigen directly coated on the plates. Recombinant MOMP was produced in COS-7 cells, transiently transfected with pcDNA1:: MOMP A, as described previously [19] .
For the determination of antibody titres in serum, 1/1000 and 1/2000 dilutions of cross-reactive biotinylated anti-chicken/turkey IgG (H+L) antibody (Invitrogen) and peroxidase-conjugated streptavidin (Invitrogen) were used, respectively. Anti-MOMP immunoglobulin titres were presented as the reciprocal of the highest serum dilution that gave an optical density (OD 405 ) above the cut-off value. The cut-off value was the mean OD of a negative African grey parrot serum ± twice S.D.
Lymphocyte proliferative responses
Leukocytes were isolated from the spleen of each budgerigar, at 21 days post challenge. Lymphocyte proliferative tests were performed as previously described [21] . Briefly, non-adherent cells were grown in duplicate in 96-well tissue culture plates at 6 · 10 5 cells in 150 lL of Dulbecco modified Eagle medium (DMEM) supplemented with 20% heat-inactivated foetal calf serum (FCS; Integro, Zaandam, The Netherlands), 1% non-essential amino acids (Life Technologies), 1% sodium pyruvate (Life Technologies), 1% L-glutamine (Life Technologies), 1% gentamycine (Life Technologies) and 5 · 10 À5 M b-mercaptoethanol (b-ME; Life Technologies). For antigen proliferation, 20 lg of rMOMP was added to individual wells. Negative and positive controls included cells stimulated with either plain medium or with 10 lg Concanavalin A (Con A), respectively. The cells were incubated at 39.5°C in a humidified incubator with 5% CO 2 . Con A or antigen-induced proliferation was measured by incorporation of 3 H-thymidine (1 lCi/well) during the last 16 h of culture, at days 2 (Con A) and 6 (DNA primed groups), respectively. Cultures were harvested onto glass fibre filter strips with a cell harvester (Skatron, Liers, Norway). The radioactivity incorporated into the DNA was measured with a b-scintillation counter (Perkin-Elmer, Life Science, Brussels, Belgium) and was expressed as a stimulation index (SI: mean counts per minute in the presence of antigen divided by the mean counts per minute in the absence of antigen).
Statistics
The two-tailed Student t-test, Mann-Whitney and Fisher Exact test were employed for statistical analyses. The results were considered significantly different at the level of p < 0.05.
RESULTS
Clinical signs
Clinical signs were first observed at five days post challenge. At that time, two placebo-vaccinated birds showed mild dyspnoea. Another placebo-vaccinated bird had diarrhoea (green watery droppings) and was shaking his head showing a sign of rhinitis. Vaccinated birds appeared healthy. From day 6 onwards till the end of the experiment, all placebo-vaccinated birds showed severe dyspnoea and diarrhoea; all but one (87.5%) had fluffy feathers. Three of eight birds (37.5%) showed lethargy and 2 of 8 birds (25%) were shaking their heads regularly (Fig. 1) . Clinical signs in the placebo-vaccinated group were most severe from post inoculation day 6 till 15. In the vaccinated group, 2 of 8 birds (25%) had diarrhoea at post inoculation day 11, 4 of 8 birds (50%) showed dyspnoea from post inoculation day 10 till 13 and at the same time 5 of 8 (62.5%) birds had fluffy feathers and 1 of 8 birds (12.5%) were lethargic. At euthanasia, at 21 days post challenge, only 1 of 8 (12.5%) vaccinated birds showed fluffy feathers and was less active. All other vaccinated birds were more active as compared to the placebo-vaccinated control group since 3 of 4 male birds were flaunting and some birds even played with the toys (mirror and bell) inside the cage. During the experiment, 2 of 8 (25%) vaccinated birds lost 7 and 7.7% of their body weight, respectively. In the placebo-vaccinated group, 6 of 8 (75%) birds lost 2.5, 2.6, 3, 5, 8.1 and 15% of their body weight, respectively. Overall, placebo-vaccinated bird pairs showed significantly (p < 0.001) higher mean culture scores as compared to the placebo-vaccinated control group (Fig. 2) . At 21 days post challenge, only 2 of 8 (25%) cloacal swabs of the vaccinated birds were positive with a mean immunofluorescence score of 0.37. On the contrary, all (100%) cloacal swabs of the placebo-vaccinated budgerigars were culture positive with a mean immunofluorescence score of 3.25.
Macroscopic lesions
At euthanasia, budgerigars were examined for the presence of macroscopic lesions. The scoring system for macroscopic lesions is presented in Table I . Lesion scores in individual birds of vaccinated and placebo-vaccinated groups are presented in Table II . Macroscopic lesions were clearly more severe in the placebo-vaccinated group, with prominent lesions in especially the respiratory tract and the spleen since all budgerigars showed focal to diffuse fibrinous airsacculitis, bilateral congestion to bilateral pneumonia and a slightly to severely enlarged spleen. Additionally, all birds showed congestion of the gut, all but one (12.5%) had a congested liver, 5 of 8 (62.5%) showed serous to fibrinous adhesive pericarditis, 3 of 8 (37.5%) showed slightly to moderately enlarged kidneys and 2 of 8 (25%) showed necrosis of the conchae. Macroscopic lesions in the vaccinated group were less severe and as in the placebo-vaccinated group mainly located in the respiratory tract and the spleen. The two groups were significantly different for macroscopic lesions in all tissues with the exception of the conchae and spleen (p < 0.05). Actually, all vaccinated No further lesions were observed in this group.
Cp. psittaci presence in different tissues
Immunofluorescence staining of frozen tissue sections of the placebo-vaccinated control group revealed strong chlamydial replication in the upper (conchae and trachea) and lower (lungs and airsacs) respiratory tract of all placebo-vaccinated budgerigars (Fig. 3) . With the exception of the pericard of one bird, replication was less prominent in the pericard, liver, kidney and gut of placebo-vaccinated budgerigars. However, all placebo-vaccinated birds experienced a systemic infection since bacterial replication was clearly observed outside the respiratory tract resulting in faecal shedding in all birds until the end of the experiment at 21 days post challenge. The infection probably also spread throughout the body of immunised birds since faecal shedding occurred in all four vaccinated bird pairs from 7 until 14 days post challenge. However, the infection seems to be eliminated more efficiently as demonstrated by diminished faecal shedding during subsequent days and by the absence of bacteria in 6 of 8 (75%) cloacal swabs, at 21 days post challenge. Notwithstanding this, replicating Cp. psittaci organisms were still present in the upper and especially lower respiratory tract of all but one (87.5%) vaccinated budgerigars at 21 days post challenge. The presence of Cp. psittaci were significantly (p < 0.05) different in all tissues of two groups except conchae.
MOMP antibody responses
All budgerigars had anti-MOMP antibodies (titre of 60 to 120) before being vaccinated with the Cp. psittaci genotype A vaccine pcDNA1:: MOMP A or the placebo vaccine pcDNA1 (Fig. 4) . MOMP antibody titres were elevated at least four-fold in all pcDNA1::MOMP A vaccinated birds, except for bird number 8, in which the MOMP antibody titre was raised only two-fold. The effect of the booster vaccination was apparently less spectacular since antibody titres following pcDNA1::MOMP A booster vaccination were only raised in 3 of 8 (37.5%) immunised budgerigars. Following challenge, antibody titres remained identical in 4 of 8 (50%), declined in 3 of 8 (37.5%) and rose in 1 of 8 (12.5%) immunised budgerigars. 
DISCUSSION
Reported human psittacosis cases are most often related to contact with Cp. psittaci infected poultry (ducks and turkeys) or Psittaciformes. Psittaciformes are kept in specialised breeding facilities, zoos and quarantine stations, but with respect to public health the increasing habit of keeping cockatoos, parrots, parakeets and lories as pets in many households, needs even more attention. Vaccination of Psittaciformes against Cp. psittaci infections might diminish the zoonotic risk, but successful vaccination could also improve the breeding performances of captive Psittaciformes and their general health status. Commercial Cp. psittaci vaccines are non existent.
In the present study, pcDNA1::MOMP A immunised budgerigars were significantly protected against severe clinical signs and lesions following challenge with a very high dose (10 8 TCID 50 ) of the highly virulent homologous Cp. psittaci genotype A strain, 89/1051. Placebo-vaccinated budgerigars showed severe clinical signs and lesions and in contrast to the vaccinated birds, excreted high amounts of Cp. psittaci for at least 3 weeks post challenge. However, notwithstanding the severity of the disease, none of the placebo-vaccinated control budgerigars died. This might be due to the preexisting anti-MOMP serum antibody titres detected in all budgerigars prior to the experimental infection. Indeed, pharyngeal and cloacal swabs taken prior to the experimental infection were negative in both nested PCR and culture, but nevertheless, all budgerigars must at least once have been infected, during their stay in the breeding facility since they all had pre-existing MOMP serum antibody titres. Indeed, the prevalence of Cp. psittaci infections is high among Psittaciformes [23] and therefore previous exposure to the organism is hardly surprising. Moreover, Cp. psittaci serum antibody titres in Psittaciformes can remain for months.
Interestingly, DNA vaccination could significantly reduce clinical signs, macroscopic lesions, bacterial excretion as well as chlamydial replication, even in the presence of pre-existing serum antibodies. Maybe not surprisingly, since MOMP antibody titres in pre-sera were rather low (maximum 120) and experimental DNA immunisation is known to be effective in turkeys having high maternal antibody titres [14] . Nevertheless, this could be an essential observation regarding future vaccination, since Cp. psittaci genotype A strains are endemic in Psittaciformes and most birds, if not all, will have antibodies against the organism.
As demonstrated before, serum antibodies did not protect against a respiratory Cp. psittaci infection, since all placebo-vaccinated controls got sick, even when having (low) pre-existing MOMP-serum antibody titres. We have no information on protective mucosal antibody titres in these birds prior to immunisation, but the experimental infective dose was extremely high, thus clinical disease in placebo-vaccinated budgerigars was probably inevitable. It might be interesting to determine the protective capacity of the DNA vaccine using lower infective doses.
Budgerigars 2 and 8, responding best to both primo and booster vaccinations and showing no secondary antibody responses upon challenge were best protected. This has also been observed following MOMP-based DNA immunisation in SPF turkeys. In turkeys, the best protection occurred in immunised turkeys that upon challenge did not demonstrate secondary antibody responses, since the bacteria were probably unable to replicate to boosting levels [14, 20, 22] . During former DNA vaccination studies in turkeys, placebo-vaccinated birds showed a primary antibody response upon challenge. In the present study, birds 13 and 16 showed a MOMP specific immune response following immunisation with the placebo vaccine, which could only mean that they experienced a Cp. psittaci infection during the first 3 weeks of the experiment. However, pharyngeal and faecal swabs of these 2 birds were PCR and culture negative at the day of the experimental infection, and at that time, 2 weeks post booster (placebo) vaccination, antibody titres were lower than after the primary vaccination. Placebo-vaccinated birds 13 and 16 were most severely infected. Maybe, these 2 birds were Cp. psittaci ''carriers'' and handling them reactivated the persistent infection. However, bacterial shedding by these 2 birds prior to the experimental infection must have been low, since their cage mates (birds number 12 and 15) did not become infected.
Currently, we have no real explanation for the absence of a significant antibody response in all but one (bird number 16) non-vaccinated controls following infection. Maybe, circulating antibodies remained longer in vaccinated birds and serum antibodies in placebo-vaccinated birds were more difficult to detect since most antibodies were ''captured'' by the extremely high amount of bacteria presenting in these heavily infected birds.
Evidence for the mobilisation of T cell memory in response to challenge was shown by the significantly increased spleen lymphocyte proliferative response upon challenge when compared to the placebo-vaccinated control group.
The essential observation of this report is that a codon-optimised, MOMP-based DNA vaccine is capable of circumventing the influence of circulating antibody inhibition. Budgerigars in the present study showed relatively moderate levels of pre-existing circulating antibodies and a totally inhibited antibody response to the vaccine construct in the presence of higher circulating antibody titres cannot be excluded. However, circulating antibody titres affected neither the induction of vaccinespecific T cell response nor significant protection in budgerigars. Therefore, prime-boost DNA vaccination may be useful for preventing Cp. psittaci infections in Psittaciformes, a bird population in which Cp. psittaci infections are nearly endemic. In addition, research on DNA vaccination in persistently infected birds would be useful in order to study possible clearance of the infection by DNA immunisation.
